<p>A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient’s Suitability for Immune Checkpoint Inhibition</p>
Michael Wessolly(Essen University Hospital), Fabian Mairinger(University of Duisburg-Essen), Kurt Werner Schmid(Essen University Hospital), Thomas Mairinger(Helios Klinikum Emil von Behring), Sabrina Borchert(Essen University Hospital), Jens Kollmeier(Helios Klinikum Emil von Behring), Anna Streubel(Helios Klinikum Emil von Behring), Robert Walter(Ruhrlandklinik), Elena Mairinger(University of Duisburg-Essen), Wilfried Eberhardt(National Center for Tumor Diseases), Torsten Blum(MSB Medical School Berlin), Robert A. Werner(MaineGeneral Medical Center), Susann Stephan-Falkenau(Helios Klinikum Emil von Behring), Sergej Griff(Helios Klinikum Emil von Behring), Torsten Bauer(Helios Klinikum Emil von Behring)
Cited by 7
Related Papers
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
A new form of amyloid protein associated with chronic hemodialysis was identified as β2-microglobulin
|Biochemical and Biophysical Research Communications|1985|987
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
|Journal of Clinical Oncology|2017|872